Vertex Pharmaceuticals VRTX Net debt
Discontinued — last reported Q1 '26
Net debt at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's net debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's net debt?
- Vertex Pharmaceuticals (VRTX) reported net debt of -$3.52B in Q1 2026.
- How has Vertex Pharmaceuticals's net debt changed year-over-year?
- Vertex Pharmaceuticals's net debt decreased by 15.9% year-over-year, from -$3.04B to -$3.52B.
- What is the long-term trend for Vertex Pharmaceuticals's net debt?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's net debt has grown at a 10.4% compound annual growth rate (CAGR), from -$1.86B to -$3.05B.
- What does net debt mean?
- Debt left over after using all the company's cash to pay it down.
- How do you interpret net debt?
- A negative value means net cash — more cash than debt, a position of strength. The numerator of net-debt/EBITDA, the most common leverage yardstick.
- How does net debt compare across companies?
- Most informative as net-debt/EBITDA; cash-rich balance sheets can show large total debt yet little or negative net debt.